Krishna Vaddi
2021
In 2021, Krishna Vaddi earned a total compensation of $7M as Chief Executive Officer at Prelude Therapeutics, a 40% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $265,688 |
|---|---|
| Option Awards | $6,224,234 |
| Salary | $544,192 |
| Total | $7,034,114 |
Vaddi received $6.2M in option awards, accounting for 88% of the total pay in 2021.
Vaddi also received $265.7K in non-equity incentive plan and $544.2K in salary.
Rankings
In 2021, Krishna Vaddi's compensation ranked 1,731st out of 12,415 executives tracked by ExecPay. In other words, Vaddi earned more than 86.1% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,731 out of 12,415 | 86th |
Division Manufacturing | 640 out of 5,508 | 88th |
Major group Chemicals And Allied Products | 236 out of 2,378 | 90th |
Industry group Drugs | 198 out of 2,099 | 91st |
Industry Pharmaceutical Preparations | 134 out of 1,549 | 91st |
Source: SEC filing on April 29, 2022.
Vaddi's colleagues
We found three more compensation records of executives who worked with Krishna Vaddi at Prelude Therapeutics in 2021.